Evidence map›Paper›PMID 41115891›Full record

ArticleNature communications2025

Astrocytic-OTUD7B ameliorates murine experimental autoimmune encephalomyelitis by stabilizing glial fibrillary acidic protein and preventing inflammation.

Kunjan Harit, Wenjing Yi, Andreas Jeron, Jakob Schmidt, Ruth Beckervordersandforth, Emanuel Wyler, Artür Manukyan, Martina Deckert, Helena Radbruch, Thomas Conrad and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Altered Erythrocyte Function via TLR9-ox-mtDNA Binding Links Mitochondrial Oxidative Damage to Systemic Inflammation in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kunjan HaritInstitute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
Wenjing YiInstitute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
Andreas JeronInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Jakob SchmidtInstitute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Ruth BeckervordersandforthInstitute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-3617-7567
Emanuel WylerBerlin Institute for Medical Systems Biology (BIMSB), Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.ORCID http://orcid.org/0000-0002-9884-1806
Artür ManukyanBerlin Institute for Medical Systems Biology (BIMSB), Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Martina DeckertDepartment of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Helena RadbruchInstitute of Neuropathology, Charité-University Medicine Berlin, Institute of Neuropathology, Berlin, Germany.ORCID http://orcid.org/0000-0001-6941-3397
Thomas ConradGenomics Technology Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0001-5618-6295
Janine AltmüllerGenomics Technology Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Markus LandthalerBerlin Institute for Medical Systems Biology (BIMSB), Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.ORCID http://orcid.org/0000-0002-1075-8734
Xu Wang *Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0001-8428-9339
Gopala Nishanth *Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0002-7280-5663
Dirk Schlüter *Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany. Schlueter.dirk@mh-hannover.de.ORCID http://orcid.org/0000-0003-1478-3328

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) CRC 854, project A5
6 · The paper itself

Abstract

Astrocytes are central to the pathogenesis of multiple sclerosis (MS); however, their regulation by post-translational ubiquitination and deubiquitination is unresolved. This study shows that the deubiquitinating enzyme OTUD7B in astrocytes protects against murine experimental autoimmune encephalomyelitis (EAE), a model of MS, by limiting neuroinflammation. RNA-sequencing of isolated astrocytes and spatial transcriptomics show that in EAE, OTUD7B downregulates chemokine expression in astrocytes of inflammatory lesions, which is associated with reduced recruitment of encephalitogenic CD4

Indexed as

AstrocytesDeubiquitinating EnzymesEncephalomyelitis, Autoimmune, ExperimentalGlial Fibrillary Acidic ProteinAnimalsCD4-Positive T-LymphocytesFemaleInflammationMiceMice, Inbred C57BLMultiple SclerosisNF-kappa BReceptor-Interacting Protein Serine-Threonine KinasesTumor Necrosis Factor-alphaUbiquitinationDeubiquitinating EnzymesGlial Fibrillary Acidic Proteinglial fibrillary astrocytic protein, mouseNF-kappa BReceptor-Interacting Protein Serine-Threonine KinasesTumor Necrosis Factor-alpha

Identifiers

PMID41115891
PMCPMC12537900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.